BioSpace News Archive

AliveGen USA Inc. is delighted to announce the successful completion of its Phase 1b multiple-ascending dose (MAD) clinical trial for ALG-801.

Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI ® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease.

Journey Medical Corporation announced today that the FDA has accepted the Company’s New Drug Application (“NDA”) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults.

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of results in The Lancet Neurology from the pivotal, Phase 3 BouNDless trial (NCT04006210) evaluating the efficacy, safety and tolerability of investigational ND0612.

SENISCA, an award-winning biotechnology company developing RNA-based senotherapeutics to treat age-related disease, announces it has raised an additional £3.7 million in funding.

Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated the Phase III clinical study results for its non-surgical treatment candidate for cervical high-grade squamous intraepithelial lesions Cevira®.

OBI Pharma, Inc. announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate.

Arrayjet, a leading provider of inkjet liquid-handling solutions, announced that its ArrayPlex™ discovery platform has been selected by Immunome, Inc., a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to expand its in-house high-throughput screening tools.

CytoMed Therapeutics Limited has obtained board approval to launch, subject to certain terms and conditions, a pilot program to isolate and cryo-store peripheral blood mononuclear cells for and as a reward to loyal shareholders of CytoMed on a complimentary basis.